There is an urgent need for the development of new approaches to the treatment of Alzheimer’s disease (AD). AD is the most common form of dementia accounting for up to 80% of all cases. Each week in Australia there are 1,700 newly diagnosed cases.
Oxytocin is the gold standard therapy for the prevention and treatment for PPH, but currently exists only as an injection product that requires refregerated supply and storage. As a consequence, many women do not have access to this essential life-saving medicine.